Report #2837860

Overview

Sex

Unknown

Age

Age unknown

State

OK

Recovered

Unknown

Vaccinated

—

Onset

—

Days to onset

—

Hospital days

—

Symptoms (1)

Symptom narrative

administered an intramuscular dose instead of subcutaneously; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a patient who received MMR (Priorix) (batch number 4N222, expiry date 13-SEP-2026) for prophylaxis. On an unknown date, the patient received Priorix. On an unknown date, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: administered an intramuscular dose instead of subcutaneously). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 16-APR-2025 Pharmacist called to ask, one of the pharmacist administered an intramuscular dose of Priorix instead of subcutaneously, which led subcutaneous injection formulation administered by other route. The reporter asked did have any guidance on this topic, did need to revaccinate. The reporter consented to follow up.